查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1863484

抗发炎治疗药物市场依治疗类别、作用机制、给药途径、通路、适应症和最终用户划分－2025年至2032年全球预测

Anti-Inflammatory Therapeutics Market by Therapeutic Class, Mechanism Of Action, Route Of Administration, Distribution Channel, Indication, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗发炎治疗市场将成长至 1,596.9 亿美元，复合年增长率为 5.52%。

关键市场统计数据
基准年 2024 1038.5亿美元
预计年份：2025年 1094.9亿美元
预测年份 2032 1596.9亿美元
复合年增长率 (%) 5.52%

整合临床奖励、相关人员激励和策略重点，为决策者建构现代抗发炎治疗格局

发炎性疾病治疗领域呈现出快速的科学进步、不断变化的临床范式和日益复杂的商业性环境。分子生物学和免疫学的进步拓展了临床医生可用的治疗手段，而患者的期望和支付方日益严格的审查则凸显了药物安全性、长期疗效和真实世界疗效的重要性。本文概述了当前的治疗环境，并综合奖励了共同影响药物研发和商业化进程的临床驱动因素、监管影响和相关人员。

转化医学的突破性进展正在为多种治疗模式创造机会，涵盖从靶向细胞激素抑製剂到调节细胞内信号传导的口服小分子药物等。然而，传统抗发炎药物仍然是控制急性症状和手术全期管理的核心，凸显了整合式医疗模式的必要性。本节结合临床观点和市场导向的视角，为后续分析奠定基础，重点在于阐述治疗方法差异化、剂型和分销策略如何影响药物的接受度和生命週期规划。

本执行摘要旨在提供平衡且基于证据的叙述，以支持策略优先排序。它重点阐述了治疗创新与未满足的临床需求相契合的领域、治疗模式转变将如何影响相关人员的行为，以及应指导投资决策的专案考量。简而言之，本导言旨在引导读者了解影响抗发炎领域治疗药物开发和取得的关键因素。

对科学突破、适应性监管途径和商业性压力进行综合观点，正在从根本上改变治疗创新和获取途径的动态。

抗发炎领域的蓬勃发展得益于科学、监管和商业性三方面关键转折点的汇聚，这些转折点正在重塑治疗方法的发现、开发和应用方式。近年来，治疗策略显着从广泛的免疫抑制转向靶向调节特定的发炎通路，这重新定义了人们对疗效、安全性和长期疾病控制的预期。同时，监管路径也不断发展，以适应新的治疗方式和适应性开发策略，迫使申办方在计画设计早期就纳入监管策略。

在商业方面，支付方和医疗系统正利用真实世界数据 (RWE) 和基于价值的合约来寻找能够展现持续疗效和成本效益的治疗方案。这种压力促使生产商将试验终点与以患者为中心的疗效和卫生经济学指标更加紧密地结合。此外，药物传递技术和远端医疗的创新正在拓展用药途径，催生新的分销策略和以患者为中心的支援服务，从而影响患者的依从性和留存率。

这些累积效应正在建构一个更为复杂但也充满机会的生态系统，其中治疗方法差异化呈现多维度特征。科学进步使得疾病生物学标靶化成为可能，监管调整促进了创新研发框架的形成，而商业性相关人员也日益重视可验证的价值。因此，能够整合临床证据产生、与支付方合作以及灵活商业化计画的机构，将更有利于驾驭不断变化的市场环境。

深入分析2025年美国关税调整对整个治疗产品组合的供应链韧性、生产策略和产品供应的影响

关税政策和贸易趋势会对医药原料和成品的供应和成本结构产生微妙而显着的影响。 2025年美国关税调整为供应链规划、筹资策略和国际采购决策引入了新的变数。製造商和经销商正在重新评估供应商所在地，寻找替代製造地，并审查库存政策，以维持供应的连续性并保护其利润率结构。

这些调整对注射剂和生物製药行业尤其重要，因为这些行业的低温运输物流和契约製造关係与生产计划紧密相关。一些公司加快了垂直整合和产能投资，以降低跨国成本波动带来的风险。同时，随着越来越多的企业寻求降低地缘政治风险并缩短关键疗法的前置作业时间，近岸外包和区域製造地也日益受到重视。

除了生产环节，支付者和医疗系统也可能受到间接影响，因为它们需要调整采购惯例以适应成本结构的变化。医疗服务提供者正在修订药品目录和集团采购协议，以在确保临床适用性的同时维持价格可负担性。总而言之，这种情况凸显了建立具有韧性的供应链、基于情境的财务模型以及与相关人员积极沟通的重要性，以维持产品供应并确保患者获得治疗。

透过对治疗领域、作用机制、给药途径、分销管道、适应症和终端用户趋势进行全面細項分析，深入了解与实际开发和商业化挑战相关的因素。

从精细的市场区隔观点来看，不同治疗领域、作用机制、给药途径、分销管道、适应症和终端用户都面临着不同的策略挑战，这些挑战各自为产品开发和商业化带来了独特的机会和限制。按治疗领域划分，市场涵盖了缓解疾病抗风湿药（DMARDs）、 Janus激酶抑製剂、非类固醇消炎剂（NSAIDs）和磷酸二酯酶抑制剂（PDE抑制剂），此外还包括生物製药和糖皮质激素，每种药物对临床证据、生产复杂性和上市后安全性监测的要求各不相同。在作用机转分类方面，治疗方法标靶Cyclooxygenase路径、白细胞介素讯号连锁、 Janus激酶级联反应、磷酸二酯酶、肿瘤坏死因子等。这种多样化的作用机制需要个人化的生物标记策略和差异化的临床终点。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 整合生物製药递送平台以增强标靶发炎消退
  • 针对发炎小体介导的疾病路径的新型小分子抑制剂的出现
  • 利用人工智慧对患者进行分层，引入个人化抗发炎疗法
  • 开发口服胜肽製剂以提高慢性发炎疾病患者的用药依从性
  • 增加对基于微生物组的肠道发炎管理干预策略的投资
  • 用于增强抗炎化合物皮肤渗透性的扩展型局部奈米载体系统
  • 监管简审类加快了治疗发炎性疾病（存在高度未满足需求）药物的核准流程

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：依治疗类别分類的抗发炎药市场

  • 生物製药
  • 皮质类固醇
  • 缓解疾病抗风湿药物
  • Janus激酶抑制剂
  • 非类固醇消炎剂
  • 磷酸二酯酶抑制剂

9. 按作用机转分類的抗发炎治疗药物市场

  • Cyclooxygenase抑制剂
  • 白细胞介素抑制剂
  • Janus激酶抑制剂
  • 磷酸二酯酶抑制剂
  • 肿瘤坏死因子抑制剂

第十章 按给药途径分類的抗发炎治疗药物市场

  • 口服
  • 肠外
    • 肌肉内注射
    • 静脉注射
    • 皮下注射
  • 外用药物
    • 奶油
    • 凝胶
    • 软膏

第十一章 按分销管道分類的抗发炎治疗药物市场

  • 医院药房
  • 网路药房
  • 零售药房

第十二章：按适应症分類的抗发炎治疗药物市场

  • 气喘和肺部疾病
  • 痛风
  • 发炎性肠道疾病
    • 克隆氏症
    • 溃疡性大肠炎
  • 骨关节炎
  • 银屑病
  • 类风湿性关节炎

第十三章 按最终用户分類的抗发炎治疗市场

  • 诊所
  • 居家照护
  • 医院
  • 专业医疗机构

第十四章 各地区抗发炎治疗药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 抗发炎治疗药物市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：各国抗发炎治疗药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • AbbVie Inc.
    • Johnson & Johnson
    • Amgen Inc.
    • Novartis AG
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • Sanofi SA
Product Code: MRR-5C6F41F5B03B

The Anti-Inflammatory Therapeutics Market is projected to grow by USD 159.69 billion at a CAGR of 5.52% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 103.85 billion
Estimated Year [2025] USD 109.49 billion
Forecast Year [2032] USD 159.69 billion
CAGR (%) 5.52%

Framing the contemporary anti-inflammatory therapeutics landscape by synthesizing clinical innovation, stakeholder incentives, and strategic priorities for decision-makers

The therapeutic landscape for inflammatory disorders is characterized by rapid scientific progress, shifting clinical paradigms, and intensifying commercial complexity. Advances in molecular biology and immunology have expanded the toolbox available to clinicians, while patient expectations and payer scrutiny have elevated the importance of comparative safety, long-term outcomes, and real-world effectiveness. This introduction frames the current environment by synthesizing clinical drivers, regulatory influences, and stakeholder incentives that collectively shape development and commercialization pathways.

Translational breakthroughs have created opportunities across a spectrum of modalities, from targeted cytokine inhibitors to orally administered small molecules that modulate intracellular signaling. At the same time, traditional anti-inflammatory agents remain central to acute symptom control and perioperative management, reinforcing the need for integrated care models. By combining clinical insight with market-oriented perspectives, this section sets the groundwork for subsequent analysis, clarifying how therapeutic differentiation, delivery format, and distribution strategy influence adoption and lifecycle planning.

The objective of this executive summary is to present a balanced, evidence-informed narrative that supports strategic prioritization. It emphasizes where therapeutic innovation aligns with unmet clinical need, how shifting treatment paradigms affect stakeholder behavior, and what programmatic considerations should guide investment decisions. In short, the introduction is intended to orient readers to the principal forces shaping therapeutic development and access in the anti-inflammatory domain.

An integrated view of scientific breakthroughs, adaptive regulatory pathways, and commercial pressures that are fundamentally altering treatment innovation and access dynamics

Momentum in the anti-inflammatory space is driven by convergent scientific, regulatory, and commercial inflection points that are reshaping how therapies are discovered, developed, and adopted. Recent years have seen a pronounced pivot from broad immunosuppression toward targeted modulation of discrete inflammatory pathways, which has recalibrated expectations for efficacy, safety, and long-term disease control. Concurrently, regulatory pathways have evolved to accommodate novel modalities and adaptive development approaches, prompting sponsors to embed regulatory strategy early in program design.

Commercially, payers and health systems are leveraging real-world evidence and value-based contracting to distinguish treatments that demonstrate durable benefit and cost offsets. This pressure has encouraged manufacturers to align trial endpoints more closely with patient-centered outcomes and health economic measures. Additionally, technological innovations in drug delivery and telemedicine have broadened access pathways, enabling novel channel strategies and patient-centric support services that can influence adherence and persistence.

The cumulative effect is a more complex but opportunity-rich ecosystem in which therapeutic differentiation is multi-dimensional. Scientific advances permit more precise targeting of disease biology, regulatory adaptations encourage innovative development frameworks, and commercial stakeholders increasingly demand demonstrable value. As a result, organizations that integrate clinical evidence generation, payer engagement, and agile commercialization planning will be best positioned to navigate the evolving terrain.

A nuanced analysis of how 2025 United States tariff adjustments are influencing supply chain resilience, manufacturing strategy, and product availability across therapeutic portfolios

Tariff policies and trade dynamics can exert a subtle yet material influence on the availability and cost structure of pharmaceutical inputs and finished products. Changes to United States tariffs in 2025 have introduced new variables for supply chain planning, procurement strategy, and international sourcing decisions. Manufacturers and distributors have responded by reassessing supplier footprints, qualifying alternate manufacturing sites, and re-evaluating inventory policies to maintain continuity of supply and to protect margin structures.

These adjustments have been particularly relevant for parenteral products and biologics, where cold-chain logistics and contract manufacturing relationships are tightly integrated with production timelines. In some instances, firms have accelerated vertical integration or capacity investments to mitigate exposure to cross-border cost fluctuations. Concurrently, emphasis on nearshoring and regional manufacturing hubs has increased, as organizations seek to reduce geopolitical risk and to shorten lead times for critical therapeutic agents.

Beyond manufacturing, payers and health systems may see indirect effects as procurement practices adapt to changed cost bases. Providers are reassessing formularies and group purchasing arrangements to preserve affordability while ensuring clinical adequacy. Overall, the tariff landscape underscores the importance of resilient supply chains, scenario-based financial modeling, and proactive stakeholder communication to sustain product availability and to preserve patient access.

Comprehensive segmentation-driven insights that map therapeutic class, mechanism, delivery, channels, indications, and end-user dynamics to practical development and commercialization imperatives

A granular segmentation lens reveals distinct strategic imperatives across therapeutic class, mechanism of action, route of administration, distribution channel, indication, and end user, each presenting unique opportunities and constraints for product development and commercialization. Based on Therapeutic Class, the market spans Biologics and Corticosteroids as well as Disease Modifying Antirheumatic Drugs, Janus Kinase Inhibitors, Nonsteroidal Anti-Inflammatory Drugs, and Phosphodiesterase Inhibitors, with each class posing different demands for clinical evidence, manufacturing complexity, and post-marketing safety surveillance. Based on Mechanism Of Action, therapies target Cyclooxygenase pathways, Interleukin signaling, Janus Kinase cascades, Phosphodiesterase enzymes, and Tumor Necrosis Factor, and the mechanistic diversity necessitates tailored biomarker strategies and differentiated clinical endpoints.

Based on Route Of Administration, therapeutic delivery choices include Oral, Parenteral, and Topical formats, where parenteral administration divides further into Intramuscular, Intravenous, and Subcutaneous approaches and topical treatments are delivered via Creams, Gels, and Ointments; these delivery distinctions influence adherence profiles, healthcare utilization patterns, and the complexity of manufacturing and distribution. Based on Distribution Channel, therapies move through Hospital Pharmacy networks, Online Pharmacy platforms, and Retail Pharmacy outlets, and each channel carries different requirements for cold-chain, patient support, and reimbursement interactions. Based on Indication, clinical targets include Asthma And Pulmonary Diseases, Gout, Inflammatory Bowel Disease, Osteoarthritis, Psoriasis, and Rheumatoid Arthritis, with Inflammatory Bowel Disease further categorized into Crohn's Disease and Ulcerative Colitis; indication-specific natural history affects trial design, responder definitions, and long-term safety monitoring. Based on End User, settings span Clinic, Home Care, Hospital, and Specialty Center, with each care environment influencing point-of-care delivery, patient education needs, and support service integration.

Taken together, this segmentation framework highlights that therapeutic success is contingent on aligning molecule attributes with the operational realities of manufacturing, channels, and clinical care settings. Strategic planners should consider how a therapy's class and mechanism guide evidence generation, how administration route shapes patient experience and adherence, and how distribution and end-user dynamics will affect access, uptake, and lifecycle management. In practice, cross-functional alignment between R&D, commercial, manufacturing, and market access teams is essential to translate segment-specific requirements into executable development and launch plans.

Region-specific strategic considerations that reconcile regulatory diversity, reimbursement paradigms, and infrastructure realities across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a strong influence on regulatory interactions, reimbursement pathways, and commercial execution, with each geography presenting distinctive clinical paradigms and operational priorities. In the Americas, healthcare systems vary from highly privatized to public payer-dominated models, driving heterogeneity in formulary decisions, access timelines, and patient support program requirements. Clinical practice patterns and guideline adoption in this region influence comparative effectiveness expectations and the evidence standards that payers and providers demand.

In Europe, Middle East & Africa, regulatory harmonization efforts coexist with significant variation in reimbursement capacity and health technology assessment methodologies. Manufacturers must navigate diverse pricing environments, local guideline adoption, and varying degrees of infrastructure for specialty care, which affects launch sequencing and patient access strategies. Capacity constraints in certain markets can also influence distribution and cold-chain investments.

In Asia-Pacific, rapid adoption of innovative therapies is often balanced against affordability pressures and evolving regulatory frameworks that can accelerate approval for therapies addressing high unmet need. Local manufacturing partnerships and regional clinical development programs are frequently used to support access and meet regulatory expectations. Across all regions, cross-border supply chain resilience, pharmacovigilance harmonization, and culturally tailored patient support models are critical for ensuring sustainable access and maximizing clinical impact.

How leading firms are combining scientific differentiation, strategic partnerships, and lifecycle tactics to optimize therapeutic pipelines and demonstrate payer-aligned value

Competitive behavior among leading companies reflects a mix of scientific differentiation, strategic partnerships, and portfolio optimization. Industry players are prioritizing targeted therapies with clear mechanistic rationales and have been investing in biologics and small molecules that offer improved safety and specificity compared with older broad-spectrum agents. Cross-sector collaborations and licensing arrangements are widespread as firms seek to complement internal capabilities with external innovation, accelerate time to clinic, and de-risk late-stage development.

Manufacturers are also placing an increased emphasis on life-cycle management tactics, including reformulations, novel delivery systems, and indication expansion strategies to extend therapeutic relevance. In parallel, companies are investing in real-world evidence generation, patient engagement platforms, and outcomes-based contracting models to demonstrate value to payers and health systems. Organizationally, there is a trend toward integrated teams that combine clinical development, market access, and commercial functions to ensure that evidence packages align with payer expectations and provider needs.

These competitive dynamics underscore the importance of agility, data-driven decision-making, and strategic partnering. Enterprises that can efficiently translate mechanistic insight into differentiated products, while simultaneously building robust evidence generation and access strategies, are positioned to navigate both clinical and commercial complexities.

Practical and prioritized actions for executives to align R&D, manufacturing, market access, and commercial teams to ensure resilient launches and sustained therapeutic adoption

Industry leaders should adopt an integrated approach that aligns early-stage scientific choices with downstream access and commercial requirements. Initiatives should include embedding payer and health economics input at the earliest program design stages to ensure that trial endpoints and health outcome measures will be credible to reimbursement stakeholders. Simultaneously, investments in manufacturing flexibility and geographic diversification will safeguard supply continuity and reduce exposure to trade disruptions.

Commercial plans must prioritize patient-centric delivery models and digital support mechanisms that improve adherence and enable remote monitoring of therapeutic response. Strategic partnerships with clinical networks, specialty pharmacies, and technology vendors can accelerate patient access and reduce the burden on traditional distribution channels. Moreover, life-cycle management should be treated as a continuous process that encompasses reformulation, delivery innovation, and indication sequencing to sustain clinical relevance.

Finally, organizations should institutionalize agile governance frameworks that facilitate cross-functional decision-making, rapid evidence integration, and scenario-based planning. These practical steps will enable companies to translate clinical innovation into durable commercial success while maintaining alignment with payer expectations and patient needs.

Transparent methodology combining expert interviews, targeted secondary review, and cross-sectional analytic techniques to validate clinical, regulatory, and operational insights

The research underpinning this executive summary synthesizes primary qualitative interviews, targeted secondary literature review, and structured analysis of regulatory and policy changes. Key informant interviews included clinical thought leaders, supply chain executives, market access specialists, and therapeutic area experts to capture multi-stakeholder perspectives. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, and technical white papers that contextualize mechanism-specific evidence and delivery considerations.

Analytical methods combined thematic synthesis with cross-sectional mapping of segmentation attributes to identify where clinical innovation intersects with operational constraints. Evidence validation steps included triangulation of interview findings with published clinical data and supply chain disclosures. Limitations and uncertainties are acknowledged, and sensitivity to evolving regulatory and trade dynamics was incorporated through scenario-based analysis. The methodology emphasizes transparency in source attribution and reproducibility of analytic choices to support informed decision-making.

Conclusion synthesizing how therapeutic innovation, evidence alignment, and operational execution collectively determine long-term success and patient impact in inflammatory diseases

In summary, the anti-inflammatory therapeutics landscape is being reshaped by precise mechanistic targeting, adaptive regulatory expectations, and heightened demands for demonstrable real-world value. These forces create both opportunities and responsibilities for developers, payers, and providers to collaborate on evidence generation, supply chain resilience, and patient-centered care models. Therapeutic differentiation increasingly requires alignment across molecule design, delivery format, and market access strategies to ensure uptake and sustainable patient benefit.

Moving forward, stakeholders who integrate clinical evidence with pragmatic operational planning will be best positioned to deliver meaningful outcomes while navigating commercial complexity. Sustained success depends not only on scientific innovation but also on the ability to orchestrate manufacturing, regulatory, and payer engagements in a coordinated fashion. The conclusion reinforces that strategic foresight, cross-functional execution, and a relentless focus on patient outcomes are the foundational elements for enduring impact in the anti-inflammatory domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of biologic drug delivery platforms to enhance targeted inflammation resolution
  • 5.2. Emergence of novel small molecule inhibitors addressing inflammasome-mediated disease pathways
  • 5.3. Adoption of artificial intelligence in patient stratification for personalized anti-inflammatory therapy
  • 5.4. Development of oral peptide formulations improving compliance in chronic inflammatory conditions
  • 5.5. Rising investment in microbiome-based interventions for gut inflammation management strategies
  • 5.6. Expansion of topical nanocarrier systems to increase skin permeation of anti-inflammatory compounds
  • 5.7. Regulatory fast track designations accelerating approval timelines for high unmet need inflammatory drugs

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Inflammatory Therapeutics Market, by Therapeutic Class

  • 8.1. Biologics
  • 8.2. Corticosteroids
  • 8.3. Disease Modifying Antirheumatic Drugs
  • 8.4. Janus Kinase Inhibitors
  • 8.5. Nonsteroidal Anti-Inflammatory Drugs
  • 8.6. Phosphodiesterase Inhibitors

9. Anti-Inflammatory Therapeutics Market, by Mechanism Of Action

  • 9.1. Cyclooxygenase Inhibitors
  • 9.2. Interleukin Inhibitors
  • 9.3. Janus Kinase Inhibitors
  • 9.4. Phosphodiesterase Inhibitors
  • 9.5. Tumor Necrosis Factor Inhibitors

10. Anti-Inflammatory Therapeutics Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Topical
    • 10.3.1. Creams
    • 10.3.2. Gels
    • 10.3.3. Ointments

11. Anti-Inflammatory Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Anti-Inflammatory Therapeutics Market, by Indication

  • 12.1. Asthma And Pulmonary Diseases
  • 12.2. Gout
  • 12.3. Inflammatory Bowel Disease
    • 12.3.1. Crohn's Disease
    • 12.3.2. Ulcerative Colitis
  • 12.4. Osteoarthritis
  • 12.5. Psoriasis
  • 12.6. Rheumatoid Arthritis

13. Anti-Inflammatory Therapeutics Market, by End User

  • 13.1. Clinic
  • 13.2. Home Care
  • 13.3. Hospital
  • 13.4. Specialty Center

14. Anti-Inflammatory Therapeutics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Anti-Inflammatory Therapeutics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Anti-Inflammatory Therapeutics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. AbbVie Inc.
    • 17.3.2. Johnson & Johnson
    • 17.3.3. Amgen Inc.
    • 17.3.4. Novartis AG
    • 17.3.5. Pfizer Inc.
    • 17.3.6. F. Hoffmann-La Roche Ltd
    • 17.3.7. Merck & Co., Inc.
    • 17.3.8. Bristol-Myers Squibb Company
    • 17.3.9. Eli Lilly and Company
    • 17.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. ANTI-INFLAMMATORY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. ANTI-INFLAMMATORY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-INFLAMMATORY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISEASE MODIFYING ANTIRHEUMATIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY JANUS KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CREAMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ASTHMA AND PULMONARY DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY GOUT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CROHN'S DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ULCERATIVE COLITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA ANTI-INFLAMMATORY THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA ANTI-INFLAMMATORY TH